Global Spasticity Treatment

Spasticity Treatment Comprehensive Study by Type (Physical Treatment, Medicine Treatment), Application (Children, Adults), End User (Hospital, Research Laboratories, Others) Players and Region - Global Market Outlook to 2026

Spasticity Treatment Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 4.18%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Spasticity Treatment Market Scope
Spasticity is a condition in which tightness of the muscles takes place due to muscles contraction. It is generally caused by damage to the spinal cord or brain which controls voluntary movement of the body. The increasing number of patients with spasticity driving the demand for novel treatment. For instance, the American Association of Neurological Surgeons there is 12 million people worldwide affected by spasticity. Further, growing healthcare infrastructure in the developing economies expected to drive the demand for spasticity treatment market over the forecasted period.

According to AMA, the Global Spasticity Treatment market is expected to see growth rate of 4.18%

Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Spasticity Treatment market throughout the predicted period.

Codman & Shurtleff, Inc. (United States), Medtronic, Inc. (Ireland), InMed Pharmaceuticals, Inc. (Canada), Ipsen (France), Allergan plc (Ireland), Pfizer Inc. (United States), Orient Pharma Co., Ltd. (Taiwan), MediciNova, Inc. (United States), Roche Holding AG (Switzerland) and UCB S.A. (Belgium) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Sanofi (France) and Taj Pharmaceuticals Limited (India).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
The study have segmented the market of Global Spasticity Treatment market by Type (Physical Treatment and Medicine Treatment), by Application (Children and Adults) and Region with country level break-up.

On the basis of geography, the market of Spasticity Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

21st June 2019, Allergan plc announced that the Food and Drug Administration approved supplemental biologics application BOTOX of the company for the treatment of pediatric patients with upper limb spasticity in the age group of 2 to 17 year.
“The U.S. Food and Drug Administration (FDA) has approved BOTOX for the treatment of lower limb spasticity in adult patients to decrease the severity of increased muscle stiffness in ankle and toe muscles. BOTOX is the first and only botulinum toxin product to be approved by the FDA to treat multiple muscle groups of the upper (elbow, wrist, fingers, and thumb) and lower limbs that may be impacted by spasticity.”

Market Trend
  • Emphasizing On Novel Treatment for Spasticity
  • Growing Popularity of Physical Therapy

Market Drivers
  • Growth in Geriatric Population
  • Rising Prevalence of Muscles Related Disorders

Opportunities
  • Rising Number of Screening Procedures
  • Growing Healthcare Infrastructure in the Developing Economies

Restraints
  • Stringent Government Regulations Regarding Medical Treatments
  • High Cost Associated With Spasticity Treatment

Challenges
  • Long Term Process of Physical Therapy
  • Lack of Awareness about the Diseases in the Low and Middle Income Group Countries


Key Target Audience
Spasticity Treatment Providers, Potential Investors, Associations, Organizations, Forums, and Alliances, Government Bodies and Departments, Research Institutes, Business Consulting Firms and Others

Report Objectives / Segmentation Covered

By Type
  • Physical Treatment
  • Medicine Treatment
By Application
  • Children
  • Adults
By End User
  • Hospital
  • Research Laboratories
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growth in Geriatric Population
      • 3.2.2. Rising Prevalence of Muscles Related Disorders
    • 3.3. Market Challenges
      • 3.3.1. Long Term Process of Physical Therapy
      • 3.3.2. Lack of Awareness about the Diseases in the Low and Middle Income Group Countries
    • 3.4. Market Trends
      • 3.4.1. Emphasizing On Novel Treatment for Spasticity
      • 3.4.2. Growing Popularity of Physical Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Spasticity Treatment, by Type, Application, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Spasticity Treatment (Value)
      • 5.2.1. Global Spasticity Treatment by: Type (Value)
        • 5.2.1.1. Physical Treatment
        • 5.2.1.2. Medicine Treatment
      • 5.2.2. Global Spasticity Treatment by: Application (Value)
        • 5.2.2.1. Children
        • 5.2.2.2. Adults
      • 5.2.3. Global Spasticity Treatment by: End User (Value)
        • 5.2.3.1. Hospital
        • 5.2.3.2. Research Laboratories
        • 5.2.3.3. Others
      • 5.2.4. Global Spasticity Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Spasticity Treatment (Price)
      • 5.3.1. Global Spasticity Treatment by: Type (Price)
  • 6. Spasticity Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Codman & Shurtleff, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Medtronic, Inc. (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. InMed Pharmaceuticals, Inc. (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Ipsen (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Allergan plc (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Orient Pharma Co., Ltd. (Taiwan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. MediciNova, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Roche Holding AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. UCB S.A. (Belgium)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Spasticity Treatment Sale, by Type, Application, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Spasticity Treatment (Value)
      • 7.2.1. Global Spasticity Treatment by: Type (Value)
        • 7.2.1.1. Physical Treatment
        • 7.2.1.2. Medicine Treatment
      • 7.2.2. Global Spasticity Treatment by: Application (Value)
        • 7.2.2.1. Children
        • 7.2.2.2. Adults
      • 7.2.3. Global Spasticity Treatment by: End User (Value)
        • 7.2.3.1. Hospital
        • 7.2.3.2. Research Laboratories
        • 7.2.3.3. Others
      • 7.2.4. Global Spasticity Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Spasticity Treatment (Price)
      • 7.3.1. Global Spasticity Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Spasticity Treatment: by Type(USD Million)
  • Table 2. Spasticity Treatment Physical Treatment , by Region USD Million (2015-2020)
  • Table 3. Spasticity Treatment Medicine Treatment , by Region USD Million (2015-2020)
  • Table 4. Spasticity Treatment: by Application(USD Million)
  • Table 5. Spasticity Treatment Children , by Region USD Million (2015-2020)
  • Table 6. Spasticity Treatment Adults , by Region USD Million (2015-2020)
  • Table 7. Spasticity Treatment: by End User(USD Million)
  • Table 8. Spasticity Treatment Hospital , by Region USD Million (2015-2020)
  • Table 9. Spasticity Treatment Research Laboratories , by Region USD Million (2015-2020)
  • Table 10. Spasticity Treatment Others , by Region USD Million (2015-2020)
  • Table 11. South America Spasticity Treatment, by Country USD Million (2015-2020)
  • Table 12. South America Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 13. South America Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 14. South America Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 15. Brazil Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 16. Brazil Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 17. Brazil Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 18. Argentina Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 19. Argentina Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 20. Argentina Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 21. Rest of South America Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 22. Rest of South America Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 23. Rest of South America Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 24. Asia Pacific Spasticity Treatment, by Country USD Million (2015-2020)
  • Table 25. Asia Pacific Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 26. Asia Pacific Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 27. Asia Pacific Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 28. China Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 29. China Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 30. China Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 31. Japan Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 32. Japan Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 33. Japan Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 34. India Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 35. India Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 36. India Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 37. South Korea Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 38. South Korea Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 39. South Korea Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 40. Taiwan Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 41. Taiwan Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 42. Taiwan Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 43. Australia Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 44. Australia Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 45. Australia Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 49. Europe Spasticity Treatment, by Country USD Million (2015-2020)
  • Table 50. Europe Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 51. Europe Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 52. Europe Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 53. Germany Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 54. Germany Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 55. Germany Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 56. France Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 57. France Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 58. France Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 59. Italy Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 60. Italy Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 61. Italy Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 62. United Kingdom Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 63. United Kingdom Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 64. United Kingdom Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 65. Netherlands Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 66. Netherlands Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 67. Netherlands Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 68. Rest of Europe Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 69. Rest of Europe Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 70. Rest of Europe Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 71. MEA Spasticity Treatment, by Country USD Million (2015-2020)
  • Table 72. MEA Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 73. MEA Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 74. MEA Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 75. Middle East Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 76. Middle East Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 77. Middle East Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 78. Africa Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 79. Africa Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 80. Africa Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 81. North America Spasticity Treatment, by Country USD Million (2015-2020)
  • Table 82. North America Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 83. North America Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 84. North America Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 85. United States Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 86. United States Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 87. United States Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 88. Canada Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 89. Canada Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 90. Canada Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 91. Mexico Spasticity Treatment, by Type USD Million (2015-2020)
  • Table 92. Mexico Spasticity Treatment, by Application USD Million (2015-2020)
  • Table 93. Mexico Spasticity Treatment, by End User USD Million (2015-2020)
  • Table 94. Spasticity Treatment: by Type(USD/Units)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Spasticity Treatment: by Type(USD Million)
  • Table 106. Spasticity Treatment Physical Treatment , by Region USD Million (2021-2026)
  • Table 107. Spasticity Treatment Medicine Treatment , by Region USD Million (2021-2026)
  • Table 108. Spasticity Treatment: by Application(USD Million)
  • Table 109. Spasticity Treatment Children , by Region USD Million (2021-2026)
  • Table 110. Spasticity Treatment Adults , by Region USD Million (2021-2026)
  • Table 111. Spasticity Treatment: by End User(USD Million)
  • Table 112. Spasticity Treatment Hospital , by Region USD Million (2021-2026)
  • Table 113. Spasticity Treatment Research Laboratories , by Region USD Million (2021-2026)
  • Table 114. Spasticity Treatment Others , by Region USD Million (2021-2026)
  • Table 115. South America Spasticity Treatment, by Country USD Million (2021-2026)
  • Table 116. South America Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 117. South America Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 118. South America Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 119. Brazil Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 120. Brazil Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 121. Brazil Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 122. Argentina Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 123. Argentina Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 124. Argentina Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 125. Rest of South America Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 126. Rest of South America Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 127. Rest of South America Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 128. Asia Pacific Spasticity Treatment, by Country USD Million (2021-2026)
  • Table 129. Asia Pacific Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 130. Asia Pacific Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 131. Asia Pacific Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 132. China Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 133. China Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 134. China Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 135. Japan Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 136. Japan Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 137. Japan Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 138. India Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 139. India Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 140. India Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 141. South Korea Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 142. South Korea Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 143. South Korea Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 144. Taiwan Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 145. Taiwan Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 146. Taiwan Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 147. Australia Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 148. Australia Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 149. Australia Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 150. Rest of Asia-Pacific Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 151. Rest of Asia-Pacific Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 152. Rest of Asia-Pacific Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 153. Europe Spasticity Treatment, by Country USD Million (2021-2026)
  • Table 154. Europe Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 155. Europe Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 156. Europe Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 157. Germany Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 158. Germany Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 159. Germany Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 160. France Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 161. France Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 162. France Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 163. Italy Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 164. Italy Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 165. Italy Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 166. United Kingdom Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 167. United Kingdom Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 168. United Kingdom Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 169. Netherlands Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 170. Netherlands Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 171. Netherlands Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 172. Rest of Europe Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 173. Rest of Europe Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 174. Rest of Europe Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 175. MEA Spasticity Treatment, by Country USD Million (2021-2026)
  • Table 176. MEA Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 177. MEA Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 178. MEA Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 179. Middle East Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 180. Middle East Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 181. Middle East Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 182. Africa Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 183. Africa Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 184. Africa Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 185. North America Spasticity Treatment, by Country USD Million (2021-2026)
  • Table 186. North America Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 187. North America Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 188. North America Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 189. United States Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 190. United States Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 191. United States Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 192. Canada Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 193. Canada Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 194. Canada Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 195. Mexico Spasticity Treatment, by Type USD Million (2021-2026)
  • Table 196. Mexico Spasticity Treatment, by Application USD Million (2021-2026)
  • Table 197. Mexico Spasticity Treatment, by End User USD Million (2021-2026)
  • Table 198. Spasticity Treatment: by Type(USD/Units)
  • Table 199. Research Programs/Design for This Report
  • Table 200. Key Data Information from Secondary Sources
  • Table 201. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Spasticity Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Spasticity Treatment: by Application USD Million (2015-2020)
  • Figure 6. Global Spasticity Treatment: by End User USD Million (2015-2020)
  • Figure 7. South America Spasticity Treatment Share (%), by Country
  • Figure 8. Asia Pacific Spasticity Treatment Share (%), by Country
  • Figure 9. Europe Spasticity Treatment Share (%), by Country
  • Figure 10. MEA Spasticity Treatment Share (%), by Country
  • Figure 11. North America Spasticity Treatment Share (%), by Country
  • Figure 12. Global Spasticity Treatment: by Type USD/Units (2015-2020)
  • Figure 13. Global Spasticity Treatment share by Players 2020 (%)
  • Figure 14. Global Spasticity Treatment share by Players (Top 3) 2020(%)
  • Figure 15. Global Spasticity Treatment share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Codman & Shurtleff, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Codman & Shurtleff, Inc. (United States) Revenue: by Geography 2020
  • Figure 19. Medtronic, Inc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 20. Medtronic, Inc. (Ireland) Revenue: by Geography 2020
  • Figure 21. InMed Pharmaceuticals, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 22. InMed Pharmaceuticals, Inc. (Canada) Revenue: by Geography 2020
  • Figure 23. Ipsen (France) Revenue, Net Income and Gross profit
  • Figure 24. Ipsen (France) Revenue: by Geography 2020
  • Figure 25. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 26. Allergan plc (Ireland) Revenue: by Geography 2020
  • Figure 27. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Orient Pharma Co., Ltd. (Taiwan) Revenue, Net Income and Gross profit
  • Figure 30. Orient Pharma Co., Ltd. (Taiwan) Revenue: by Geography 2020
  • Figure 31. MediciNova, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. MediciNova, Inc. (United States) Revenue: by Geography 2020
  • Figure 33. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Roche Holding AG (Switzerland) Revenue: by Geography 2020
  • Figure 35. UCB S.A. (Belgium) Revenue, Net Income and Gross profit
  • Figure 36. UCB S.A. (Belgium) Revenue: by Geography 2020
  • Figure 37. Global Spasticity Treatment: by Type USD Million (2021-2026)
  • Figure 38. Global Spasticity Treatment: by Application USD Million (2021-2026)
  • Figure 39. Global Spasticity Treatment: by End User USD Million (2021-2026)
  • Figure 40. South America Spasticity Treatment Share (%), by Country
  • Figure 41. Asia Pacific Spasticity Treatment Share (%), by Country
  • Figure 42. Europe Spasticity Treatment Share (%), by Country
  • Figure 43. MEA Spasticity Treatment Share (%), by Country
  • Figure 44. North America Spasticity Treatment Share (%), by Country
  • Figure 45. Global Spasticity Treatment: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Codman & Shurtleff, Inc. (United States)
  • Medtronic, Inc. (Ireland)
  • InMed Pharmaceuticals, Inc. (Canada)
  • Ipsen (France)
  • Allergan plc (Ireland)
  • Pfizer Inc. (United States)
  • Orient Pharma Co., Ltd. (Taiwan)
  • MediciNova, Inc. (United States)
  • Roche Holding AG (Switzerland)
  • UCB S.A. (Belgium)
Additional players considered in the study are as follows:
Sanofi (France) , Taj Pharmaceuticals Limited (India)
Select User Access Type

Key Highlights of Report


Oct 2021 204 Pages 58 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Spasticity Treatment Quantitative research analysis
Global Spasticity Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Spasticity Treatment study can be customized to meet your requirements. The market size breakdown by type [Physical Treatment and Medicine Treatment], by end use application [Children and Adults].
The Spasticity Treatment Market is gaining popularity and expected to see strong valuation by 2026.
According to AMA, the Global Spasticity Treatment market is expected to see growth rate of 4.18%.

Know More About Global Spasticity Treatment Report?

Have a Query? Click Here

Other Related Reports

Tuberculosis Drug Comprehensive Study by Type (First-line Anti-TB Drugs, Second-line Anti-TB Drugs), Application (Active TB, Latent TB), End User (Hospital, Clinic, Durgstore), Testing (TB skin test ...
$ 3350
Inflammatory Bowel Disease Comprehensive Study by Type (Anti-inflammatory Biologics, Non-Steroidal Anti-inflammatory drugs (NSAIDs), Corticosteroids), Application (Hospital, Drugs Stores), Route of A...
$ 3450
Organ Transplant Immunosuppressant Drugs Comprehensive Study by Type (Chemical Composition, Fungal Product, Biologics), Application (Liver Transplant, Kidney Transplant, Other Organ Transplant), Drug...
$ 3650
Tissue Engineering Comprehensive Study by Type (Synthetic Materials, Biologically Derived Materials, Others), Application (Orthopedics, Musculoskeletal & Spine, Neurology, Cardiology & Vascular, Skin...
$ 3450
Autoimmune Disease Therapeutics Comprehensive Study by Indication (Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, Others), Distribution Channel (Hospitals, Clinic...
$ 3750
Impingement Syndrome Comprehensive Study by Type (Structural Impingement, Functional Impingement), Application (Hospitals, Physical Therapists), Treatment (Physical Therapy, Medications (Aspirin, Nap...
$ 3750